toripalimab-tpzi
toripalimab-tpzi is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including LOQTORZI. Available dosage form: injection.
Drug Details
- Generic Name
- toripalimab-tpzi
- Brand Names
- LOQTORZI
- Application Number
- BLA761240
- Sponsor
- Coherus Oncology, Inc.
- NDC Codes
- 2
- Dosage Forms
- INJECTION
- Routes
- INTRAVENOUS
- Active Ingredients
- TORIPALIMAB
Indications and Usage
1 INDICATIONS AND USAGE LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) 1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). 1.2 Previously Treated Unresectable or Metastatic NPC LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.